HOME > ARCHIVE

ARCHIVE

BUSINESS NEWS IN BRIEF

May 3, 2004
Results of Study on Combination of PTX, CBDCA Reported

May 3, 2004
BUSINESS NEWS IN BRIEF

May 3, 2004
Zyrtec Significantly Reduces Symptoms of Pollinosis

May 3, 2004
WEBSITE NEWS

May 3, 2004
Technomics Analyzes Drugs Discontinued in Development 1985-2003

May 3, 2004
CORPORATE ROUNDUP NEWS IN BRIEF

May 3, 2004
Use of Inhalant Steroids in Asthma Treatment Delayed in Japan: JRS Meeting

April 26, 2004
Most Specialists Not Satisfied with Drugs for Autoimmune Diseases

April 26, 2004
Specialists Question Therapeutic GL on Gastric Ulcers

April 26, 2004
Keizai Doyukai Presents Recommendation, "Toward the Advanced Healthcare Nation, Nippon"

April 26, 2004
RESEARCH & DEVELOPMENT NEWS IN BRIEF

April 26, 2004
Yamanouchi Eliminates Cumulative Loss in China Business

April 26, 2004
OTC NEWS IN BRIEF

April 26, 2004
1.1% Growth in Sales by Top 18 Firms Expected in FY2003: Analyst

April 26, 2004
MEDICAL DEVICE NEWS IN BRIEF

April 26, 2004
BUSINESS NEWS IN BRIEF

April 26, 2004
Iryo Proverbs Reveal Japanese Spirit (19)

April 26, 2004
April 26, 2004
DIAGNOSTIC NEWS IN BRIEF

April 26, 2004

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…